Days drug group's operation blocked

In the transfer of new drug industry (market, interrogation) less than 10 months, Tianjin Pharmaceutical group is also eager to plan from the wholly-owned subsidiary of Tianjin Jin Hao medicine in the hands of the new drug industry to recover the holding power.　　Financial profit PO, current savings rate increase 1000% the securities Times reporter was informed that the day drug group was forced by the Ministry of Commerce to make a temporary adjustment. Chinese new drug industry recently disclosed that the controlling shareholder Jin Hao Medicine has reached an agreement with Tian Yao Group on September 16 to transfer the 44.04% equity of the new drug industry to Tian Yao Group.　　If the matter is completed, the days of medicine group will be directly involved in the new drug industry, this day before yesterday, the drug group to fade out of management while the new drug industry, Lisheng Pharmaceutical (market, interrogation) control transfer to Jin Hao medicine formed a clear contrast.　　In fact, Tian Pharmaceutical group has been a controlling shareholder in the new drug industry and Lisheng Pharmaceutical, among which the Chinese medicine industry is mainly based on TCM, is positioned as the group of Chinese Medicine listing platform, while Lisheng Pharmaceutical is focused on chemical drugs, and the new drug industry objectively exists a clear division of labor. Tian Yao Group directly holding its two pharmaceutical listed companies are not inappropriate. However, in November 2011, the new drug industry and the listing only more than a year Lisheng pharmaceutical issued a notice, said the days of drug group intends to transfer the control of the two companies to Jin Hao medicine.　　The latter, which was established in August 2011, does not carry out specific business operations, but plays a role in the reorganization of the Days Medicine group. In order to facilitate the transfer of equity, days Pharmaceutical group has been operating for one year, during which also applied for exemption from the offer of shares. Eventually, last December, Jin Hao Medicine was successfully in the new drug industry and Lisheng Pharmaceutical, and Days Medicine group was relegated to the background.　　To China Merchants Securities (market, inquiry) for the representative of some research institutions will Jin Hao medicine as the pharmaceutical group integration of medicine assets of the platform, later or through with the Tianjin state-owned Jin Lian group to achieve the overall listing in Hong Kong.　　As a matter of fact, since March this year, there has been a surge of rumours about the days of the pharmaceutical group's listing in Hong Kong, but as of now, there is no large-scale substantive action. The transfer of new drugs and Lisheng pharmaceutical control soon, days pharmaceutical group is ready to Jin Hao medicine 100% shares transferred to the Tianjin Union group wholly-owned subsidiary of the company's name.　　The move was once considered to be the prelude to the accelerated pharmaceutical asset securitization of the group in Hong Kong with Tianjin Development, Tianjin Port (market, inquiry) development and the dynasty wine industry three listed platforms, while Tianjin development is the best backdoor platform for Jin Hao medicine.　　The project has not changed quickly, the above issues have not yet been completed, days Pharmaceutical group announced the resumption of the new drug industry control, and did not disclose specific reasons. It should be pointed out that the current Lisheng pharmaceutical has not issued a notice of the transfer of similar shares.　　In other words, as of now, the days of medicine group does not intend to recover from the hands of Jin Hao medicine Lisheng Pharmaceutical 51.36% of the controlling power.　　Reporter yesterday from the new drug industry-related People's exclusive learned that the days of medicine group was really going through the development of Tianjin will Jin Hao medicine to create a group of listed platform, Jin Hao Medicine equity transfer to the Swiss benefit holding is a key step. andAnd, in the material for approval to the Ministry of Commerce, there are problems, the new drug industry fist variety of quick-impact rescue heart pill is a state secret formula, according to the relevant provisions do not allow foreign investment, and Jin Hao medicine if the implementation of capital operation in Hong Kong will be exposed to foreign investors. On the basis of this, Tian Pharmaceutical group decided to withdraw the control of the new drug industry, to avoid the foregoing provisions.　　such as Nanjing Medicine (market, interrogation) in the introduction of joint Bo posture, in order to avoid the provisions of the continuous transfer of some of the poor profitability of Chinese medicine assets.　　In the days of pharmaceutical group system, the overall profitability of the new drug industry is slightly stronger than Lisheng pharmaceutical, if the transfer of the new drug industry equity, the Jin Hao pharmaceutical assets scale and quality will be greatly reduced, it is bound to affect its valuation capacity. "The transfer of equity is a matter of the group level, and the matter does not change the operation and actual control of the company, and the company will not transfer the quick-impact rescue pill as the group seeks to develop overseas." "The above-mentioned people in the new drug industry said.